Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Oncology | Hematology
Disease Category: Leukemia

Trial Information

A Phase II Study of Dasatinib Therapy in Children and Adolescents with Ph+ Leukemia with Resistance or Intolerance to Imatinib

The purpose of this study is to find out if dasatinib is effective in children and adolescents with chronic myeloid leukemia (CML) or acute lymphoblastic leukemia (ALL) who prove resistant or intolerant to imatinib or relapsed after imatinib. The side effects this oral investigational drug may have in children and adolescents will also be studied.

Inclusion Criteria:

Ph+ CML in chronic, accelerated or blast phase or Ph+ ALL with imatinib-resistant disease or intolerance

Lansky or Karnofsky scale > 50

Life expectancy >= 12 weeks

Adequate hepatic renal function

Exclusion Criteria:

• Eligibility for potentially-curative therapy including hematopoietic stem-cell transplantation
• Symptomatic CNS involvement (other than signs and symptoms caused by leptomeningeal disease)
• Isolated extramedullary disease
• Prior therapy with dasatinib

Phoenix Children's Hospital
1919 E. Thomas Road Outpatient Building B
Phoenix, AZ 85016
Phone: 16025465067
Fax: 16025460277

View Google Map

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.